Summary
Johnson & Johnson (JNJ) has announced the successful completion of its acquisition of Actelion Ltd. through its subsidiary, Janssen Holding GmbH. The all-cash tender offer, which began in January 2017, saw approximately 92.51% of Actelion's outstanding shares tendered, representing a significant strategic move for JNJ. The total consideration paid amounted to approximately $27.8 billion, funded through JNJ's existing cash reserves. Importantly, as part of this transaction, Actelion's drug discovery and early-stage clinical development assets have been demerged into a new, independent company called Idorsia Ltd. JNJ will not directly own these early-stage assets but will hold a significant stake in Idorsia, initially 9.9% and potentially up to 32% through a convertible note. This structure allows JNJ to focus on Actelion's marketed products while retaining exposure to future innovation through its investment in Idorsia.
Key Highlights
- 1Johnson & Johnson successfully completed the acquisition of Actelion Ltd. for approximately $27.8 billion in cash.
- 2The tender offer, conducted by subsidiary Janssen Holding GmbH, was accepted by 92.51% of Actelion's outstanding shares.
- 3Actelion's drug discovery and early-stage development assets were demerged into a new entity, Idorsia Ltd., which is now listed on the SIX Swiss Exchange.
- 4Johnson & Johnson will not acquire Idorsia directly but will hold a significant equity stake (initially 9.9% and up to 32% via convertible note) in the new company.
- 5The acquisition was funded using Johnson & Johnson's available cash on hand.
- 6Johnson & Johnson intends to acquire the remaining untendered Actelion shares through a short-form merger or squeeze-out procedure.
- 7Detailed financial statements and pro forma information for the acquired business will be filed via amendment within 71 days.